Objective: Un®ltered coffee raises serum LDL cholesterol in humans, owing to the presence of the diterpenes cafestol and kahweol. Norwegians with a chronic high intake of un®ltered coffee also had elevated serum levels of lipoprotein(a), an LDL-like particle which is insensitive toward dietary interventions. We now experimentally studied the in¯uence of coffee diterpenes on lipoprotein(a) levels. Design: Four randomised controlled trials. Subjects: Healthy, normolipidemic volunteers. Interventions: Coffee, coffee oil, and pure diterpenes for 4±24 weeks. Main outcome measures: The circulating level of lipoprotein(a). Results: In 22 subjects drinking ®ve to six strong cups of cafetiere coffee per day, the median fall in lipoprotein(a) was 1.5 mg/dL after two months (P 0.03), and 0.5 mg/dL after half a year (P b 0.05), relative to 24 ®lter coffee drinkers. Coffee oil doses equivalent to 10±20 cups of un®ltered coffee reduced lipoprotein(a) levels by up to 5.5 mg/dL (P`0.05) in two separate trials (n 12±16 per group). A puri®ed mixture of cafestol and kahweol, as well as cafestol alone, were also effective in reducing Lp(a) levels (n 10). Averaged over the four trials, each 10 mg/d of cafestol (plus kahweol)Ðthe amount present in two to three cups of cafetiere coffeeÐdecreased Lp(a) levels by 0.5 mg/dL or 4% from baseline values after four weeks (n 63). Conclusions: Coffee diterpenes are among the few dietary exceptions shown to in¯uence serum lipoprotein(a) levels. However, the Lp(a)-reducing potency of coffee diterpenes may subside in the long run, and their adverse side effects preclude their use as lipoprotein(a)-reducing agents.
Introduction
Lipoprotein(a) [Lp(a) ] is a liver-derived lipoprotein particle that is only distinguished from low-density-lipoprotein (LDL) by the covalent attachment of a large glycoprotein, apolipoprotein(a) (Dahle Ân, 1994 ). An extensive body of laboratory evidence indicates a critical role of Lp(a) in the development of atherothrombotic diseases (Marcovina & Morrisett, 1995) , which is con®rmed by most (Rosengren et al, 1990; Sigurdsson et al, 1992; Wald et al, 1994; Cremer et al, 1994; Bostom et al, 1994; Schaefer et al, 1994; Terres et al, 1995; Bostom et al, 1996) , though not all Ridker et al, 1993; Alfthan et al, 1994; Ridker et al, 1995) , prospective cohort studies. The circulating level of Lp(a) is largely under genetic control (Boerwinkle et al, 1992) , and is unaffected by many interventions known to affect LDL metabolism, including most dietary interventions (Berglund, 1995) .
The diterpenes cafestol and kahweol are lipids that are unique to coffee beans (Viani, 1986) . They are responsible for the cholesterol-raising effect of Scandinavian boiled coffee (Weusten-van der Wouw et al, 1994; Heckers et al, 1994) . Cafestol and kahweol strongly affect lipid metabolism with short-term intake (Bak & Grobbee, 1989; Aro et al, 1987; van Dusseldorp et al, 1991; Ahola et al, 1991; Aro et al, 1990; Urgert et al, 1996a) as well as in life-long consumers of un®ltered coffee (Bùnaa et al, 1988; Stensvold et al, 1989; Weusten-van der Wouw et al, 1994; Pietinen et al, 1990; Lindahl et al, 1991) . We recently found that consumption of boiled coffee was also associated with Lp(a) levels; the median Lp(a) level in Norwegians who were life-long consumers of boiled coffee was 65% higher than in matched ®lter coffee drinkers (Urgert et al, 1996b) .
We now report the effects of preparations rich in cafestol and kahweol on Lp(a) levels in healthy, normolipidemic volunteers in four independent experiments. The effects on serum lipids and liver enzymes have been reported elsewhere (Weusten-van der Wouw et al, 1994; Urgert et al, 1996a; Urgert et al, 1997a) .
Methods

Subjects
Participants were recruited through advertisements in newspapers and university buildings. Most subjects were young, nonobese, and normolipidemic (Table 1) , and all were apparently healthy as indicated by a medical questionnaire and by the absence of anaemia, glucosuria, or proteinuria. None took medications known to affect serum lipid levels. The experimental protocols, which were approved by the local human ethics committee, were carefully explained to the volunteers and their written informed consent was obtained.
Subjects were asked to maintain their usual diet and lifestyle, and not to consume more than twenty drinks containing alcohol per week. They were allowed to use paper®ltered or instant coffee, as these are free from diterpenes . All subjects kept daily records of illness, medication use, and deviations from the protocol.
Treatments and designs
Between 1991 and 1995, we carried out four randomised trials. We gave ®ltered versus un®ltered coffee in trial A, placebo versus coffee oil in trials B and C, and cafestol versus a mixture of cafestol and kahweol in trial D. The experimental designs are given in Figure 1 .
Trial AÐun®ltered vs ®ltered coffee. This was a randomised, parallel controlled study. After a run-in period of four weeks on ®ltered coffee, subjects consumed 0.9 l of either ®ltered or cafetiere (also called`French press') coffee per day for 24 weeks. All ground coffee was Roodmerk (Douwe Egberts, Utrecht, The Netherlands), a blend of Arabica and Robusta beans widely used in the Netherlands (van Dusseldorp et al, 1991) . Cafetiere coffee provided 38 mg of cafestol and 33 mg of kahweol and ®ltered coffee less than 1 mg of either diterpene per day. Six subjects withdrew during the treatment period for personal reasons, and one was withdrawn as he started taking drugs of potential hepatoxicity daily during the trial.
Trials B and CÐcoffee oil vs placebo oil. These were double-blind, randomised parallel controlled studies. All participants ®rst received for 1±2 weeks placebo oil which was a 3:2 (w/w) mixture of sun¯ower oil and palm oil. After randomization, subjects continued on either placebo oil or coffee oil for four weeks. Daily amounts of diterpenes provided by the coffee oil were 85 mg of cafestol and 103 mg of kahweol in trial B, and 57 mg of cafestol and 69 mg of kahweol in trial C. In trial C, a third group of subjects received coffee oil that was stripped of cafestol and kahweol.
There were no dropouts in trial B. Two subjects withdrew from trial C for reasons unrelated to treatment.
Trial DÐcafestol plus kahweol vs cafestol alone. This was a double-blind, randomised cross-over study. Participants received placebo oil during the ®rst two weeks. During the next four weeks, half of the subjects received 64 mg of cafestol and 1 mg of kahweol dissolved in placebo oil. The other ®ve subjects received 60 mg of cafestol and 54 mg of kahweol per day, again dissolved in placebo oil. After a wash-out period of seven weeks, subjects again received placebo oil for two weeks, and supplements were switched during the next four weeks; analysed dosages of cafestol and kahweol were now 61 and 0 mg for pure cafestol, and 60 and 48 mg for the mixture, respectively. Purities of the diterpene preparations were higher than 92%; impurities consisted of free cafestol and kahweol, cafestol and kahweol dipalmitate, and palmitic acid.
Three subjects were switched to placebo after two weeks of treatment, because they exceeded our prede®ned safety limits for rises in alanine amino transferase. For these subjects, values obtained after two weeks replaced their ®nal values.
Serum analyses
Venous blood samples were taken after an overnight fast. Serum samples were obtained by centrifugation, stored at 780 C, and analysed blindly within 12 months after completion of the studies. Empty cells indicate wash-out and follow-up periods, during which no treatment was given.
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For trials B anc C, Lp(a) was measured with a solid phase two-site immunoradiometric assay (RIA) from Pharmacia Diagnostics AB (Uppsala, Sweden). The intra-and inter-assay coef®cients of variation as given by the manufacturer were 3.3 and 10.6%, respectively. The range of measurable serum Lp(a) concentrations was 1.7±84.0 mg/ dL. Sera with concentrations higher than 84.0 mg/dL were diluted and remeasured. Six out of 78 subjects had Lp(a) levels less than 1.7 mg/dL. These were designated undetectable. The results were recalculated from arbitrary units to milligrams per decilitre on the basis of the results obtained with the kit calibrators, and the value of a serum standard from Immuno A.G. (Vienna, Austria).
For trials A and D, Lp(a) was measured with an enzymelinked immuno-sorbent assay (TintElize Lo(a), Campro Scienti®c, Veenendaal, the Netherlands). The lower limit of detection of Lp(a) was 1 mg/dL. None of the subjects had levels below the detection limit. The intra-and interassay coef®cients of variation for a control pool of 44 mg/ dL as measured in our laboratory were 5.0% and 3.5%, respectively.
For all trials, sera were analysed in duplicate in two separate runs, but with one full series of samples obtained from one subject analysed within the same run. Lipids, lipoproteins, and liver enzymes in serum (Weusten-van der Wouw et al, 1994), and cafestol and kahweol in coffee preparations , were assayed as described.
Statistical analyses
We calculated the Lp(a) response of each subject by subtracting values obtained after the run-in period (baseline values) from those obtained during the treatment period (treatment values). As some of the responses showed nonGaussian distributions, we used Mann Whitney U tests to compare control and treatment groups. In trial D, responses were analysed using Wilcoxon Rank Sum tests.
Results
Diaries kept by the subjects showed that more than 98% of the diterpene preparations had been taken in each of the trials.
Trial AÐun®ltered vs ®ltered coffee. Daily consumption of ®ve cups of cafetiere coffee produced a fall in Lp(a) levels, which reached a maximum of 1.5 mg/dL after eight weeks (P 0.03), relative to ®ltered coffee (Figure 2 ). The reduction stabilised around 0.5 mg/dL (P b 0.05) between 12 and 24 weeks of consumption.
Trials B and CÐcoffee oil vs placebo oil. In trial B, intake of 3 g of coffee oil per day for four weeks caused a median fall in Lp(a) levels of 5.3 mg/dL, relative to concurrent controls receiving placebo oil (P`0.001). In trial C, intake of 2 g/d of coffee oil reduced Lp(a) levels by 3.1 mg/dL (P 0.02). Coffee oil that was stripped of cafestol and kahweol did not affect Lp(a) levels.
Trial DÐcafestol plus kahweol vs cafestol alone. The mixture of cafestol and kahweol as well as cafestol alone both reduced Lp(a) levels by 3±4 mg/dL relative to baseline levels (Table 2 ). Relative to cafestol alone, the mixture produced a median fall in Lp(a) levels of 0.8 mg/dL, and a mean fall of 0.5 (s.e.m. 0.6) mg/dL (both P b 0.05).
Changes in Lp(a) were not associated with changes in other serum lipids and lipoproteins, or in liver enzymes (P b 0.05). In all four experiments, Lp(a) levels returned to baseline values after cessation of treatment.
We combined the individual data of the four trials and classi®ed all subjects according to initial Lp(a) value Response different from zero: P`0.01.
Coffee diterpenes reduce serum Lp(a) R Urgert et al ( Figure 3 ). On an absolute basis, individuals with high initial Lp(a) values appeared to bene®t more from diterpene intake; the median fall of Lp(a) was 70.3 mg/dL in the lowest, 73.3 mg/dL in the middle, and 76.5 mg/dL in the upper tertile in subjects who received diterpenes, each relative to the median change in the corresponding tertile of controls.
Discussion
Preparations rich in the coffee diterpenes cafestol and kahweol reduced serum Lp(a) levels in four independent experiments. Females taking oral contraceptives were randomised over control and treatment groups, and one of the subjects took medications on a regular basis. Bias due to hormone intake or drug therapy (Berglund, 1995) is thus unlikely. Furthermore, changes in dietary intakes, body mass, and alcohol use were minimal and similar for the control and treatment groups within each study (Weustenvan der Wouw et al, 1994; Urgert et al, 1996a; Urgert et al, 1997a) . Therefore, it is unlikely that the reductions in Lp(a) levels were due to anything else than treatment with coffee diterpenes. Despite its structural similarity to LDL, the circulating level of Lp(a) is remarkably insensitive to dietary intervention; by now, only dietary trans fatty acids have consistently been proven to be effective, as they modestly raise Lp(a) levels (Mensink et al, 1992; Nestel et al, 1992; Almendingen et al, 1995) . Fish oils (Beil et al, 1991; Haglund et al, 1994) as well as high doses of ascorbic acid (Rath, 1992) Intake of cafestol alone was effective in reducing Lp(a) levels, and the addition of kahweol had little extra effect (trial D). Cafestol may thus be the sole Lp(a)-reducing principle in coffee oil. However, this trial was too small to fully exclude an additional effect of kahweol.
Health bene®ts. Individuals with high initial values of Lp(a) showed a larger drop in Lp(a) levels than those with low initial values (Figure 3) . The median fall across the four experiments depended on the daily amount of cafestol ingested. Under the assumption that the relationship is Coffee diterpenes reduce serum Lp(a) R Urgert et al linear, each 10 mgÐthe amount present in two to three cups of cafetiere coffeeÐreduced Lp(a) levels by 0.5 mg/ dL or 4% from baseline level after four weeks (Figure 4) . We would expect the same effect with Turkish and Scandinavian boiled coffee, as these types contain similar diterpene levels per cup as cafetiere coffee. For espresso coffee, about six cups per day are needed for a similar effect . Could a lowering of Lp(a) levels with consumption of coffee diterpenes confer any health bene®t? In a metaanalysis of eleven trials with preparations rich in cafestol and kahweol, we found that each 10 mg of cafestol ingested per day raises serum total cholesterol by 0.15 mmol/L, which was mostly due to an increase in LDL cholesterol (Urgert & Katan, 1997b) . The hypercholesterolemic potency of coffee diterpenes thus overrules their potential bene®cial impact on Lp(a) levels. This is evidenced by a higher rate of coronary heart disease in coffee drinkers in Norway (Tverdal et al, 1990) , where boiled coffee is more common. Coffee diterpenes as such are thus unsuitable as a means of treatment for elevated Lp(a) levels, and a switch from ®ltered to un®ltered coffee is not warranted.
Short-term vs chronic intake. The present ®ndings contradict our previous observation in a cross-sectional study that Norwegian boiled-coffee drinkers had higher Lp(a) levels than ®lter coffee drinkers (Urgert et al, 1996b) .
The reason for this discrepancy is unknown. In our cross-sectional study and in each of the trials described here, serum samples of subjects who had ingested diterpenes and those of control subjects had been stored at 780 C for a similar period with a maximum of one year. Therefore, even if sample storing has affected Lp(a) levels, it is unlikely that it has affected the cross-sectional study and the experiments in opposite directions.
A second explanation could be the presence of some unknown confounding factor in our cross-sectional study, although the insensitivity of Lp(a) levels to environmental factors (Berglund, 1995) argues against this possibility. Still, confounding by genetic differences cannot be fully excluded: all subjects were living in Southern Norway, but more people consuming boiled coffee may have descended from ancestors originating from northern Norway, where boiled coffee is more common (Stensvold et al, 1989) .
In trial A, Lp(a) levels were depressed by up to 15% in the ®rst two months of intake of cafetiere coffee, but the effect was strongly attenuated with prolonged use (Figure  2 ). This indicates that the reducing effect of cafestol and kahweol may subside with prolonged intake. For other agents known to in¯uence the serum level of Lp(a), this could have important implications. For instance, the evidence for the Lp(a)-elevating of dietary trans fatty acids is derived from short-term experiments only (Mensink et al, 1992; Nestel et al, 1992; Almendingen et al, 1995) . The present ®ndings emphasize the need for intervention trials of longer duration in studying effects of diet or drugs on Lp(a) levels.
Mechanism. Short-term intake of coffee diterpenes raises serum levels of alanine amino transferase (Weusten-van der Wouw et al, 1994; Van Rooij et al, 1995; Urgert et al, 1996a) , which may point at disturbed hepatocyte integrity (Keil, 1990) . The alterations in serum lipids and lipoprotein levels caused by coffee diterpenes may also be due to effects on liver cell metabolism. Apolipoprotein(a) is synthesised in the liver (Kraft et al, 1989) , and circulating levels of Lp(a) are largely determined by the rate of production (Rader et al, 1993) . Indeed patients with biliary cirrhosis (Feely et al, 1992; Gregory et al, 1994; van Wesch, 1994) or other liver diseases (Gregory et al, 1994) have higher levels of lipids and liver aminotransferases, but had reduced plasma (Lp(a) levels. It is thus possible that the reduction of Lp(a) by coffee diterpenes is also due to their effect on liver cell metabolism. Crosssectional studies showed that chronic consumers of boiled (Weusten-van der Wouw et al, 1994) or espresso coffee (Casiglia et al, 1993) had no elevated levels of alanine amino transferase. However, it remains speculative whether a transient effect on liver cell integrity may also result in an adaptation of Lp(a) metabolism in the human body.
Conclusions
Coffee diterpenes, which are present in un®ltered coffee brews, are among the few dietary constituents that modulate Lp(a) levels. An advise to switch from ®ltered to un®ltered coffee is not warranted, as cafestol and kahweol exert a range of other, negative health effects. The present ®ndings also indicate that caution is needed in extrapolating results from short-term controlled trials to the chronic situation.
